Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

Andrew Blauvelt; Kim A Papp; Christopher E M Griffiths; Luis Puig; Jamie Weisman; Yves Dutronc; Lisa Farmer Kerr; Dapo Ilo; Lotus Mallbris; Matthias Augustin

doi:10.1007/s40257-018-0353-x

Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

Am J Clin Dermatol. 2018 Jun;19(3):457. doi: 10.1007/s40257-018-0353-x.

Authors

Affiliations

¹ Oregon Medical Research Center, 9495 SW Locust St., Suite G, Portland, OR, 97223, USA. [email protected].
² K Papp Clinical Research and Probity Medical Research, Waterloo, Canada.
³ Dermatology Centre, Salford Royal Hospital, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
⁴ Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
⁵ Medical Dermatology Specialists, Inc., Atlanta, GA, USA.
⁶ Eli Lilly and Company, Indianapolis, IN, USA.
⁷ Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Abstract

The article Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) written by Andrew Blauvelt.

Publication types

Published Erratum